Neogene Therapeutics (Group)

https://www.neogene.com

LinkedIn: https://www.linkedin.com/company/neogene-therapeutics

Neogene Therapeutics, Inc. is a pre-clinical stage biotechnology company pioneering development of next-generation, fully personalized engineered T cells therapies for a broad spectrum of cancers. The Company’s engineered T cells target mutated proteins found in cancer cells due to cancer-associated DNA mutations, or neo-antigens, that render tumor cells vulnerable to detection by T cells. Neogene’s proprietary technology platform aims to identify TCR genes with specificity for neo-antigens from tumor biopsies. Neogene’s novel approach intends to deliver a tailored set of TCR genes for each individual patient, which will be engineered into patient-derived T cells directing them towards neo-antigens in tumor cells, with the goal of providing a fully personalized engineered T cell therapy for cancer. *

	Start	2018-01-01 established
	Industry	TCR engineered T-cells
	Industry 2	oncology
	Person	Belldegrun, Arie (Allogene 201806 Executive Chairman before Kite Pharma CEO)

	Region	New York, NY
	Country	United States (USA)
	Street	689 Fifth Avenue 12th Floor
	City	10022 New York, NY
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Neogene Therapeutics, Inc.. (9/14/20). "Press Release: Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies". New York, NY & Amsterdam.

		Record changed: 2020-09-18